← FDA DRUG APPROVALS

FDA ANDA · ANDA206191

METRONIDAZOLE

Sponsor: INFORLIFE

APPLICATION
ANDA206191
TYPE
ANDA
ORIGINAL APPROVAL
2019-02-25
LATEST ACTION
2024-12-03
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

METRONIDAZOLE IN PLASTIC CONTAINERPrescription
METRONIDAZOLE 500MG/100ML · INJECTABLE · INJECTION

Approval history

2024-12-03Labeling · Supplement 16 · standardAP
2023-09-19Labeling · Supplement 12 · standardAP
2023-09-19Labeling · Supplement 5 · standardAP
2023-09-19Labeling · Supplement 6 · standardAP
2019-02-25UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →